 | |||||||||||||||||||||||
|
   Buy Victor Zeines book now! |
 |
Study 1
Kayhan Civelek DDS 200 Central Park South, Suite 209 New York, NY 10019 1-646-903-4833 A patient was referred to our clinic with a chief complaint of bleeding gums and halitosis. Initial examination included: clinical evaluation of intraoral soft tissue including gums, tongue and the buccal mucosa. Hard tissue examination was performed via digital x rays, and initial DNA analysis was done to determine the type of microorganism that was present in the mouth specifically in the in sulcus/periodontal pocket. Further, more periodontal evaluation with full mouth probing was performed by a periodontist. The result of initial evaluation revealed generalized active periodontitis with an average of 20-25% attachment loss. The initial treatment consisted of improving home care, scaling and root planing. Post initial four weeks evaluation revealed no change in the clinical signs of active inflammation Bleeding on Probing (BOP), the color, consistency and the texture of soft tissue did not show any improvement. The result of post scaling DNA did not show major shifts in the pathologic microbiota. New studies that were published in JADA and JAMA explain how nutrition plays a major role in improving immune response to infection. There for we decided to improve the patients' overall diet with a new supplement that is called OSTEOPRO. The patient was asked to mix one tablespoon of powder with a glass of water and drink, twice a day. After six weeks patient was evaluated to see any possible changes of the intraoral soft tissue. The color of the gingival was changed from magenta red to rose pink; it was more firm and resilient. Further more the BOP sites were reduced by 80%. Surgical treatment was performed with bone graft and he was gained the lost attachment and six months after the initial treatment these results are stable. He has supplemented his diet with OSTEOPRO ever since.
Since the result of this single case in our office we decided to perform a double blinded study in a real world private office setting. This study was designed to determine the effect of OSTEOPRO at the post initial and post surgical phase of the treatment. Ten patients in each group with similar periodontal conditions were selected. One of the group received OSTEOPRO, the other placebo. Neither the doctors nor the patient knew which group was active, which was a placebo group. Initial evaluation included pocket measurements, clinical evaluation of gingival such as color consistency, texture and BOP. Initial treatment included scaling, root planing and improving home care and supplements. Post initial evaluation 78% improvement in the clinical parameters of OSTEOPRO group where placebo group revealed only 31% improvement. SECOND PHASE - Second phase of the treatment was continuation of the first phase to the surgical treatment. Similar results were found the active group demonstrated 72% increases in the attachment level where placebo group only 26%. Further more the OSTEOPRO group maintained the new gained attachment where the placebo group lost 45% of the new attachment. Because of these results OSTEOPRO is fixed compliment of peridontal treatment in our office. Dr. Kayhan Civelek is an implantologist who serves on the Faculty of New York University, Department of Periodontology. He has no commercial interest in this product. |
||||||||||||||||||||
| |||||||||||||||||||||||
|
|||||||||||||||||||||||
